


Biocelerate is JRF's partnership model that helps sponsors cost-effectively deepen and broaden their discovery pipelines. It can be accessed by resource-constrained biotech companies to derisk pipeline assets by front-loading the screens for therapeutic class liabilities (safety/tox/ADME). Biocelerate can also help start-up/virtual drug discovery companies and academic centres increase the value of an asset prior to licensing or a fundraise. JRF augments this service offering by providing rapid turnaround times, transparent and customized packages & pricing, as well as forward integration into IND enabling GLP studies.



JRF Global is a GLP compliant (since 1996) and AAALAC certified (since 2009) global CRO with its presence in seven countries across the globe. Collaborate with JRF Global's experienced study teams to evaluate the safety profile of your lead molecule. JRF can design, synthesize, alter, and evaluate ADMET of different scaffolds to identify a back-up molecule or an improved scaffold to minimize the risk, and to enhance the chances of successful clinical trials. All of these within your easily affordable budget!

## Case study

Parameters	Lead	Mol-1	Mol-2	Mol-4	Mol-3	Mol-5	Mol-6
Solubility after addition of nitrogen	1x	≈	≈	↑↑↑↑	↑↑↑↑	≈	↑↑
Total clearance	1x	↓↓↓	↓↓↓	↑↑	↓↓↓	↓↓↓	≈
2D6 Inhibition	X	X	X	✓	✓	X	X
3A4 Inhibition	✓	✓	✓	✓	✓	X	X
2C19 Inhibition	✓	✓	✓	✓	✓	✓	X
PPB (vs. Lead)	1x	≈	≈	≈	≈	≈	1.1x

\*Offered through our partners  
≈ Similar to the Lead compound



**JRF GLOBAL**  
Pharma Solutions

Leading  Innovation - Responsibly

JRF India | JRF America | JRF Europe | HJCL Japan  
Contact us at [bd@jrfglobal.com](mailto:bd@jrfglobal.com) | [www.jrfglobal.com](http://www.jrfglobal.com)

